Literature DB >> 27365019

PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer.

Dale L Bailey1, Adrian Lee2, Bob T Li3, Stephen J Clarke4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27365019      PMCID： PMC4932355          DOI： 10.1136/bcr-2016-215645

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


× No keyword cloud information.
  3 in total

1.  90Y PET-based dosimetry after selective internal radiotherapy treatments.

Authors:  Marco D'Arienzo; Paola Chiaramida; Laura Chiacchiararelli; Angela Coniglio; Roberto Cianni; Rita Salvatori; Alberto Ruzza; Francesco Scopinaro; Oreste Bagni
Journal:  Nucl Med Commun       Date:  2012-06       Impact factor: 1.690

2.  Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT.

Authors:  Renaud Lhommel; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Jose I Bilbao; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07-18       Impact factor: 9.236

3.  SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Authors:  Guy A van Hazel; Volker Heinemann; Navesh K Sharma; Michael P N Findlay; Jens Ricke; Marc Peeters; David Perez; Bridget A Robinson; Andrew H Strickland; Tom Ferguson; Javier Rodríguez; Hendrik Kröning; Ido Wolf; Vinod Ganju; Euan Walpole; Eveline Boucher; Thomas Tichler; Einat Shacham-Shmueli; Alex Powell; Paul Eliadis; Richard Isaacs; David Price; Fred Moeslein; Julien Taieb; Geoff Bower; Val Gebski; Mark Van Buskirk; David N Cade; Kenneth Thurston; Peter Gibbs
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.